Topic: 6-OHDA mouse model

Parkinson’s disease (PD) is a neurological and neurodegenerative disease characterized by themanifestation of motor and non-motor symptoms. Among these, pain is one of the most frequent,affecting around 85% of patients and contributing to a deterioration in their quality of life.Nowadays, pain treatment in PD is still inefficient due to the lack of knowledge of the underlyingmechanisms. However, we know that pain can be modulated by the monoaminergic descendingpathways projecting to the dorsal horn of the spinal cord (DHSC). Thus, the aim of the present studyis to unravel the involvement of th

Parkinson’s disease is caused by the selective loss of the dopaminergic neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine depletion. In Parkinson’s disease therapy, dopamine loss is counteracted by the administration of the dopamine precursor L-DOPA, which is initially effective in ameliorating motor symptoms, but over time it leads to a burdening side effect of uncontrollable jerky movements, termed L-DOPA-induced dyskinesia. To date, no efficient treatment for dyskinesia exists. The dopaminergic and serotonergic systems are intrinsically linked, and a role ha